FindTrial
Sign In

Role of Dopamine Transporter in Glucose Control

Role of Dopamine Transporter in Glucose Loading of Healthy Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03466697
Enrollment
40
Registered
2018-03-15
Start date
2018-03-14
Completion date
2021-12-20
Last updated
2022-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

Healthy subjects will be enrolled in this study. Each subject will be scanned twice with F18-FP-CIT PET which is commercially available. F18-FP-CIT reflects dopamine transporter availability of striatum. Before each PET scan, subject will be injected either glucose or normal saline. Therefore, PET scan will reflect the changes of dopamine transporter availability after the injection of glucose.

Interventions

OTHERGlucose injection/Normal saline injection

Before each PET scan, subject will be injected either glucose or normal saline.

Sponsors

Pusan National University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy subjects

Exclusion criteria

* known neurologic disorder * known drug addiction * known endocrine disorder

Design outcomes

Primary

MeasureTime frameDescription
Specific binding ratio of dopamine transporter availabilitiy measured from PET scansless than 1 monthSpecific binding ratio of dopamine transporter availabilitiy measured from PET scans

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026